title: Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib.
abstract: Hairy cell leukemia (HCL) is a chronic B-cell lymphoproliferative disorder that accounts for 2% of all leukemia. Recent identification of the recurrent V600E BRAF mutation in a majority of HCL patients has led some teams to evaluate the clinical potential of vemurafenib, a BRAF V600 specific inhibitor in a limited number of refractory HCL patients. Recently, we published the case of an HCL patient successfully treated with a low dose of vemurafenib. Eight months after the ending of treatment this patient relapsed. We present here the successful retreatment of this patient with a second line of vemurafenib. Our data suggest for the first time that vemurafenib at the dose of 240 mg once a day could be sufficient to maintain a complete hematological remission after an initial induction treatment with low-dose vemurafenib (2 × 240 mg) daily without inducing major toxicity.
authors: Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.
authors: Caroline
authors: C
authors: Bailleux
authors: INSERM, U1065, TEAM 2, Nice, France ; University of Nice, Nice, France.
authors: Guillaume
authors: G
authors: Robert
authors: INSERM, U1065, TEAM 2, Nice, France ; University of Nice, Nice, France.
authors: Clémence
authors: C
authors: Ginet
authors: Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.
authors: Daniel
authors: D
authors: Re
authors: Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.
authors: Antoine
authors: A
authors: Thyss
authors: Laboratory of Hematology, CHU Nice, Nice, France.
authors: Isabelle
authors: I
authors: Sudaka
authors: Department of Pathology, Centre Antoine Lacassagne, Nice, France.
authors: Isabelle
authors: I
authors: Peyrottes
authors: Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, CHU Nice.
authors: Paul
authors: P
authors: Hofman
authors: INSERM, U1065, TEAM 2, Nice, France ; University of Nice, Nice, France.
authors: Patrick
authors: P
authors: Auberger
authors: Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.
authors: Frederic
authors: F
authors: Peyrade
keywords: V600E mutation; hairy-cell leukemia; re-treatment; relapse; vemurafenib